secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bone Biologics Corp (BBLG)
CIK:        0001419554
Form:       8-K
Filed at:   2023-12-13T23:59:59+00:00
Accession:  0001493152-23-044661
Event type: regulatory
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.07, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Stockholders approve reverse stock split; Nasdaq grants continued listing until Jan 12, 2024
--------------------------------------------------------------------------------

- Stockholders voted 1,402,685 for, 162,168 against, 16,129 abstain to authorize reverse stock split at ratio 1:5 to 1:20.
- Nasdaq Hearings Panel granted continued listing until Jan 12, 2024, subject to milestones including implementing the reverse split and meeting minimum bid price.
- Company intends to implement plan to meet milestones before Jan 12 deadline; previously received delisting notice for bid price non-compliance.
- Special meeting adjournment proposal was also approved but not needed since first proposal passed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419554/000149315223044661/0001493152-23-044661-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419554/000149315223044661/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-044661

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer